Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BRD3308 是一种高选择性的HDAC3抑制剂,IC50为 54 nM。它可激活HIV-1转录并破坏HIV-1潜伏期。它抑制由炎性细胞因子或糖脂毒性应激诱导的胰腺 β 细胞凋亡,并增加功能性胰岛素释放。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 336 | 现货 | ||
2 mg | ¥ 475 | 现货 | ||
5 mg | ¥ 747 | 现货 | ||
10 mg | ¥ 1,190 | 现货 | ||
25 mg | ¥ 2,230 | 现货 | ||
50 mg | ¥ 3,590 | 现货 | ||
100 mg | ¥ 5,250 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 795 | 现货 |
产品描述 | BRD3308 is a highly selective inhibitor of HDAC3(IC50 of 54 nM), attenuating PE-mediated phosphorylation of ERK but not JNK. |
靶点活性 | HDAC1:1260 nM , HDAC1:5100 nM (Ki) , HDAC3:29 nM (Ki) , HDAC3:54 nM , HDAC2:1340 nM , HDAC2:6300 nM (Ki) |
体内活性 | BRD3308 is a selective HDAC3 inhibitor,to reduce hyperglycaemia and increase insulin secretion in a rat model of type 2 diabetes.?At diabetes onset, an ambulatory hyperglycaemic clamp was performed.?HDAC3 inhibition improved hyperglycaemia over the study period without affecting weight gain.?At the end of the hyperglycaemic clamp, circulating insulin levels were significantly higher in BRD3308-treated rats.?Pancreatic insulin staining and contents were also significantly higher.?These findings highlight HDAC3 as a key therapeutic target for β-cell protection in type 2 diabetes[1]. |
动物实验 | Male Zucker Diabetic Fatty (Obese) rats (6-week-old); 5 mg/kg; Intraperitoneal injection; every second day |
分子量 | 287.29 |
分子式 | C15H14FN3O2 |
CAS No. | 1550053-02-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 52 mg/ml(181 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.4808 mL | 17.404 mL | 34.808 mL | 87.0201 mL |
5 mM | 0.6962 mL | 3.4808 mL | 6.9616 mL | 17.404 mL | |
10 mM | 0.3481 mL | 1.7404 mL | 3.4808 mL | 8.702 mL | |
20 mM | 0.174 mL | 0.8702 mL | 1.7404 mL | 4.351 mL | |
50 mM | 0.0696 mL | 0.3481 mL | 0.6962 mL | 1.7404 mL | |
100 mM | 0.0348 mL | 0.174 mL | 0.3481 mL | 0.8702 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BRD3308 1550053-02-5 Apoptosis Chromatin/Epigenetic DNA Damage/DNA Repair Microbiology/Virology Proteases/Proteasome HIV Protease HDAC β-cells glucolipotoxicity inflammatory Human immunodeficiency virus Histone deacetylases HDAC3 diabetes HIV-1 Inhibitor latency BRD 3308 cytokines hyperglycaemia HIV inhibit insulin BRD-3308 inhibitor